Literature DB >> 7795653

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.

M E Thompson1, R A Jensen, P S Obermiller, D L Page, J T Holt.   

Abstract

We have characterized expression of the familial breast and ovarian cancer gene, BRCA1, in cases of non-hereditary (sporadic) breast cancer and analyzed the effect of antisense inhibition of BRCA1 on the proliferative rate of mammary epithelial cells. BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive cancer. Experimental inhibition of BRCA1 expression with antisense oligonucleotides produced accelerated growth of normal and malignant mammary cells, but had no effect on non-mammary epithelial cells. These studies suggest that BRCA1 may normally serve as a negative regulator of mammary epithelial cell growth whose function is compromised in breast cancer either by direct mutation or alterations in gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795653     DOI: 10.1038/ng0495-444

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  131 in total

1.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 2.  Expression of BRCA1 and BRCA2 in normal and neoplastic cells.

Authors:  L A Chodosh
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

3.  BRCA1 interacts with components of the histone deacetylase complex.

Authors:  R I Yarden; L C Brody
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  BRCA1 partially reverses the transforming activity of the ras oncogene.

Authors:  A Kumar; C Knott; K Kuus-Reichel; M S Saedi
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 5.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

Review 6.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

7.  Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

Authors:  F Durocher; P Tonin; D Shattuck-Eidens; M Skolnick; S A Narod; J Simard
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

8.  Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).

Authors:  Nadine Andrieu; David E Goldgar; Douglas F Easton; Matti Rookus; Richard Brohet; Antonis C Antoniou; Susan Peock; Gareth Evans; Diana Eccles; Fiona Douglas; Catherine Noguès; Marion Gauthier-Villars; Agnès Chompret; Flora E Van Leeuwen; Irma Kluijt; Javier Benitez; Brita Arver; Edith Olah; Jenny Chang-Claude
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

9.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

10.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.